📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial. (2020)

First Author: Chan S

Attributed to: A randomised placebo-controlled study examining the role of anti-IgE in severe recalcitrant paediatric atopic eczema funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1001/jamapediatrics.2019.4476

PubMed Identifier: 31764962

Publication URI: http://europepmc.org/abstract/MED/31764962

Type: Journal Article/Review

Volume: 174

Parent Publication: JAMA pediatrics

Issue: 1

ISSN: 2168-6203